九典制药(300705) - 300705九典制药投资者关系管理信息20251105

Group 1: Company Performance and Market Strategy - The overall business operation in Q4 is stable, with sales proceeding as planned amidst steady market demand [2][3] - The company is implementing multi-faceted measures to address the impact of the centralized procurement of Loxoprofen Sodium Gel, focusing on expanding the outpatient market and enhancing brand development [2][3] - The company has a professional OTC team of over 200 people to drive online and offline channel development, effectively broadening market coverage [7] Group 2: Innovation and R&D Focus - The company is fully transitioning to focus on innovative drug development, with a core emphasis on chemical and traditional Chinese medicine innovations [4] - In 2025, the estimated R&D expenditure is projected to be between 250 million to 300 million CNY [6] - The company is pursuing a dual approach of independent R&D and project acquisition to enhance its innovation pipeline [4] Group 3: Product Launch and Sales Expectations - The Ketoprofen Gel was approved for market entry in 2023 and is optimistic about its market prospects as it is the first generic product listed in the national medical insurance directory [5] - The company is intensifying resource allocation towards the outpatient market and strengthening internal sales team assessments to boost sales performance [5][7] Group 4: Market Challenges and Strategic Adjustments - The company acknowledges pressure on achieving annual targets due to market challenges but is committed to promoting new products and enhancing market penetration [7] - Strategies include optimizing product positioning and increasing brand influence to expand market share [7]